MNOV
MediciNova, Inc.
There isn't enough reported data to score MNOV yet.
MNOV Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
MNOV's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
MNOV PE Valuation
MNOV has no meaningful PE right now: it lost money over the past year.
MNOV Forward outlook
There aren't enough analyst estimates for MNOV to show an outlook.
MNOV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.21 | +$0.04 |
| Q2 2026 | -$0.21 | +$0.04 |
| Q1 2026 | -$0.23 | $0.00 |
| Q4 2025 | -$0.24 | -$0.01 |
| Q3 2025 | -$0.25 | -$0.04 |
| Q2 2025 | -$0.25 | -$0.09 |
| Q1 2025 | -$0.23 | -$0.06 |
| Q4 2024 | -$0.23 | -$0.06 |
MNOV is still losing money, but less than at its worst: $0.21 per share over the past year, against $0.31 at its worst in late 2020.
MNOV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $138.6K | +12% |
| Q2 2026 | $458.4K | +241% |
MNOV's revenue is recovering but still below its 2021 peak: $138,555 last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2209% | +533 points |
| Q2 2026 | -554% | +2126 points |
| Q1 2026 | -1517% | N/A |
| Q4 2025 | -2038% | N/A |
| Q3 2025 | -2742% | N/A |
| Q2 2025 | -2680% | N/A |
| Q3 2023 | -115% | N/A |
| Q3 2021 | -9605% | N/A |
MNOV's operating margin was −2209% last quarter, up 533 points from the same quarter a year ago.
MNOV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$3.5M | +$302.6K |
| Q4 2025 | -$2M | -$85.1K |
| Q1 2025 | -$3.8M | +$84.6K |
| Q4 2024 | -$1.9M | -$1.4M |
| Q3 2024 | -$2M | -$657.8K |
| Q1 2024 | -$3.9M | -$690.8K |
| Q1 2023 | -$3.2M | +$551K |
| Q4 2021 | -$3.6M | -$1.7M |
MNOV has burned cash in almost every quarter: −$10M over the past year, against −$12M the year before.
MNOV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +157K shares |
| 1 year | +0.7% | +332K shares |
| 3 years | +0.7% | +332K shares |
| 5 years | +0.8% | +390K shares |
| Available history | +14% | +6.2M shares |
MNOV has 49M diluted shares, up 0.7% from a year ago.
MNOV Net Leverage
MNOV's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MNOV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.6 | Neutral |
| Stochastic | 4.9 | Oversold |
MNOV's weekly RSI is 47 (neutral) and its Stochastic is 5 (oversold).
MNOV PE vs Healthcare Sector
MNOV has no meaningful PE right now: it lost money over the past year.
MNOV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.62 | 14% below |
| 20 week MA | $1.60 | 13% below |
| 50 week MA | $1.51 | 7.3% below |
| 100 week MA | $1.50 | 6.7% below |
| 200 week MA | $1.67 | 16% below |
MNOV is in a downtrend: it's below all five of its weekly moving averages, and 16% below its 200-week average.
MNOV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.50 | $5.63 | -13% |
| 2021 | $5.63 | $2.79 | -50% |
| 2022 | $2.79 | $2.00 | -28% |
| 2023 | $2.00 | $1.50 | -25% |
| 2024 | $1.50 | $2.07 | +38% |
| 2025 | $2.07 | $1.27 | -39% |
| 2026 YTD | $1.27 | $1.40 | +10% |
MNOV has finished lower in five of the last six years. It's up 10% so far in 2026.